Candin for the Treatment of Common Warts
Completed · Phase 3 · NCT05889845
Conditions: Common Warts (Verruca Vulgaris)
At a glance
- Research payments reported, 2025
- $976,202
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 330
About the trial
- Sponsor
- Nielsen BioSciences, Inc.
- Tested
- Candin, Intradermal Solution (drug), Placebo (drug)
- Dates
- Started 2025-01-22; completion 2025-08-27
- Results posted
- Not yet
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response
From ClinicalTrials.gov, last updated 2025-09-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Nielsen Biosciences, Inc. reported $976,202 in research payments for this study in 2025 (23 payments).
Products named: Candin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $976,202
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.